hassan noorbazargan | Immunology | Best Researcher Award

Published on by Academic Excellence

Dr. hassan noorbazargan | Immunology | Best Researcher Award

Dr. hassan noorbazargan | Immunology | Carbon Technologies LLC | Oman 

Dr. Hassan Noorbazargan is a highly accomplished researcher specializing in biotechnology, immunology, and molecular diagnostics. He earned his Ph.D. in Medical Biotechnology from Shahid Beheshti University of Medical Sciences, Iran, where his doctoral work focused on the design and validation of advanced PCR assays for detecting HIV. His career reflects a strong combination of academic excellence and industrial expertise, spanning molecular diagnostics, vaccine production, recombinant protein development, and nanobiotechnology. Dr. Noorbazargan has held prominent roles at Carbon Technologies Co., ROJE Technologies, and the Pasteur Institute of Iran, where he contributed significantly to diagnostic assay development and vaccine quality control. His research contributions have led to impactful publications on nanocarriers, drug delivery, and novel therapeutic strategies for infectious diseases and cancer. Dedicated to advancing biotechnology and immunology, Dr. Noorbazargan continues to shape the scientific community with his innovative work, quality leadership, and pursuit of translational research.

Author Profiles

Orcid | Google Scholar

Education 

Dr. Hassan Noorbazargan pursued his Ph.D. in Biotechnology at Shahid Beheshti University of Medical Sciences, where he achieved a perfect GPA. His doctoral thesis focused on the design, development, and application of TaqMan real-time PCR for qualitative and quantitative detection of HIV, demonstrating his expertise in molecular diagnostics. Prior to this, he earned his M.Sc. in Microbiology from Islamic Azad University of Lahijan, where his thesis involved cloning and expression of the HCV core+1 protein in mammalian cells, highlighting his interest in virology and genetic engineering. He also completed his B.Sc. in Microbiology from the same university, where he developed a strong foundation in immunology, biochemistry, and cell biology. Through his academic journey, he undertook multiple research assistantships in microbiology and biotechnology labs, which helped refine his practical laboratory expertise. His educational achievements underline a consistent pursuit of excellence and research-driven learning.

Experience

Dr. Hassan Noorbazargan brings extensive experience in both academia and industry, specializing in diagnostics, vaccines, and nanobiotechnology. Currently serving as Senior Researcher & QC Head at Carbon Technologies Co., Muscat (2024–Present), he leads diagnostic kit validation for infectious diseases and ensures regulatory compliance. From 2019–2024, as Head of R&D at ROJE Technologies, he developed PCR assays for HIV, Hepatitis, and Influenza while managing technology transfer and GMP compliance. Earlier, he was a Senior R&D Specialist at Sinaclon, focusing on scaling molecular reagents and diagnostic kits. At the Pasteur Institute of Iran, he contributed as a Senior Scientist in BCG vaccine production and later as Scientific Advisor in vaccine development. His career also includes supervisory roles in clinical diagnostics and hands-on experience as a hospital lab technician. With a proven record in assay development, recombinant proteins, and nanocarriers, Dr. Noorbazargan continues to bridge research with translational healthcare solutions.

Awards and Honors

Throughout his career, Dr. Hassan Noorbazargan has earned recognition for his academic and research excellence in biotechnology and immunology. He successfully completed his Ph.D. with distinction at Shahid Beheshti University of Medical Sciences, where his groundbreaking work on HIV molecular detection positioned him as a leading scholar in molecular diagnostics. His innovative publications on nanocarriers, drug delivery systems, and novel therapeutic strategies for cancer and infectious diseases have been widely cited, reflecting their significant impact on the scientific community. He has also been acknowledged for his leadership in R&D roles, particularly in vaccine development and molecular assay validation, where his contributions directly influenced product innovation and clinical applications. In addition, Dr. Noorbazargan has participated in global training programs offered by WHO Academy, IAVI, Coursera, and edX, further strengthening his expertise. His ongoing pursuit of excellence and translational research has earned him recognition as a promising researcher in biotechnology and immunology.

Research Focus

Dr. Hassan Noorbazargan’s research is deeply rooted in immunology, nanobiotechnology, and molecular diagnostics. His focus lies in developing advanced diagnostic assays, nanocarrier-based drug delivery systems, and recombinant proteins for therapeutic and preventive medicine. A significant part of his work addresses infectious diseases such as HIV, Hepatitis, and COVID-19, where he has designed and validated cutting-edge PCR and ELISA-based assays for accurate detection. Beyond infectious diseases, his research explores innovative cancer therapies using niosomes, nanogels, and metal-organic frameworks for targeted and site-specific drug delivery. His publications highlight enhanced antibacterial, anticancer, and anti-metastatic strategies through engineered nanostructures, offering breakthroughs in precision medicine. He also contributes to vaccine research, optimizing immunogenicity assays and quality systems to improve vaccine safety and efficacy. By integrating molecular biology, immunology, and biotechnology, Dr. Noorbazargan’s research strengthens the bridge between laboratory innovation and clinical application, ultimately advancing global healthcare outcomes.

Publications

  • Narrative review on traditional medicine options for COVID-19 treatment.

  • Curcumin-loaded niosome nanocarriers for breast cancer therapy.

  • Ciprofloxacin-encapsulated niosomes for enhanced antibacterial activity.

  • Doxycycline-loaded niosomal formulation for prostate cancer treatment.

  • Niosome-loaded selenium nanoparticles for antibacterial and anticancer activities.

  • Folate-conjugated nanogels encapsulating oxaliplatin for colorectal cancer therapy.

  • Silver nanoparticles from Juniperus chinensis with anticancer properties.

  • Cefazolin-encapsulated UIO-66-NH2 nanoparticles against resistant S. aureus.

  • Folate-targeted curcumin-loaded niosomes for breast cancer treatment.

  • Biogenic AgNPs from Artemisia oliveriana for lung cancer therapy.

  • Engineered UIO-66 MOF delivering curcumin for breast cancer cells.

  • Super magnetic niosomal nanocarriers for breast cancer therapy.

Conclusion

Dr. Hassan Noorbazargan is a promising scientist whose research combines immunology, molecular diagnostics, and nanomedicine to address critical challenges in infectious diseases and cancer. With a balance of academic achievements, industrial expertise, and impactful publications, he stands as a strong candidate for global recognition in biomedical research.

 

Kiran Kharsodiya | Immunology | Women Researcher Award

Published on by Academic Excellence

Dr. Kiran Kharsodiya | Immunology | Women Researcher Award

Dr. Kiran Kharsodiya | Immunology | Mody University of Science and Technology | India

Kiran Kharsodiya is a dedicated Research Scientist and Microbiologist with over eight years of experience in clinical, pharmaceutical, and microbiological research. Currently serving as Project Research Scientist II under the ICMR-CAR-MEDTECH Project at St. John’s Research Institute, Bengaluru, Kiran has made impactful contributions in designing and executing large-scale intervention and medical device trials. His expertise lies in microbiological examination, molecular analysis, and the study of host-inflammatory pathways. Kiran holds a strong research background supported by multiple peer-reviewed publications in international journals, reflecting his commitment to advancing medical science. His doctoral research at Mody University focuses on microbiological and molecular analysis of abnormal vaginal discharge and its pathophysiological effects, bridging microbiology and women’s health. A recipient of CSIR-NET qualification in 2024, Kiran exemplifies innovation, critical thinking, and leadership in translational research. His collaborative approach and scientific rigor continue to shape impactful research outcomes with real-world clinical applications.

Author Profiles

Orcid | Google Scholar

Education

Kiran Kharsodiya has pursued a strong academic foundation in microbiology and life sciences, which has shaped his career in biomedical research. He is currently completing his Doctor of Philosophy (PhD) at Mody University, India, where his thesis focuses on “Microbiological Examination and Molecular Analysis in Abnormal Vaginal Discharge and Comparative Analysis of its Pathophysiological Effect.” His PhD integrates molecular biology with clinical microbiology to explore diagnostic and therapeutic strategies in women’s health. Kiran earned his Master of Science (Microbiology) degree from Devi Ahilya University, Indore, India, where he specialized in advanced microbiological techniques and clinical research applications. He also completed a Bachelor of Science (Industrial Microbiology) from the same university, where his academic excellence and research curiosity laid the foundation for his career. Complementing his education, he successfully qualified the prestigious CSIR-NET exam in 2024, showcasing his academic excellence and research potential.

Experience

Currently working as Project Research Scientist II at St. John’s Research Institute, Bengaluru, under the ICMR-CAR-MEDTECH Project (2024–present), Kiran Kharsodiya brings extensive expertise in microbiology and clinical trial management. His role involves designing and executing large-scale pharmaceutical, medical device, and clinical trials, with a focus on ensuring regulatory compliance and high-quality data collection. He actively contributes to Phase III trials, large intervention efficiency studies, and the development of non-medical trial protocols. His ability to coordinate daily operations, collaborate with multidisciplinary teams, and analyze clinical trial data demonstrates his strong leadership in research environments. Kiran is also skilled in publishing and disseminating research findings through scientific journals and conferences, reinforcing his contributions to the broader scientific community. With more than eight years of research experience, he has developed a reputation for innovation, scientific precision, and problem-solving, contributing significantly to advancing biomedical and microbiological research in India and beyond.

Awards and Honors

Throughout his career, Kiran Kharsodiya has consistently demonstrated academic excellence and research dedication, earning several notable distinctions. His most recent achievement includes qualifying the prestigious CSIR-NET examination in 2024, a highly competitive recognition that reflects his advanced scientific knowledge and potential for research leadership. His contributions to translational microbiological and clinical research have also been acknowledged through multiple peer-reviewed publications, a testament to his innovation and dedication. Kiran has been invited to present his findings at national and international scientific conferences, highlighting the global relevance of his work. His collaborative research within multi-institutional projects, such as the ECGRI study on endometriosis and ovarian cancer, further underscores his recognition within the scientific community. These milestones, combined with his proven ability to integrate microbiology, molecular biology, and clinical research, establish him as a promising scientist whose work continues to be recognized for both academic rigor and societal impact.

Research Focus

Kiran Kharsodiya’s research focus lies at the intersection of microbiology, immunology, and women’s health. His PhD work emphasizes microbiological examination and molecular analysis of abnormal vaginal discharge, aiming to identify pathogenic flora, host-inflammatory responses, and their pathophysiological effects. This contributes to better diagnostic and therapeutic strategies for gynecological conditions. His studies also expand into the role of biomarkers, such as cytokines and microRNAs, in diseases like endometriosis and ovarian cancer, highlighting his interest in translational research. By integrating clinical microbiology, immunological pathways, and molecular diagnostics, Kiran seeks to improve early detection and intervention in reproductive health disorders. His work extends to exploring host-pathogen interactions, inflammation markers such as IL-6, IL-1β, TNF-α, and their predictive value in microbial infections. This research bridges fundamental microbiology with clinical applications, addressing pressing healthcare challenges. His long-term goal is to advance diagnostic tools and contribute meaningfully to global women’s healthcare solutions.

Publications

  • Protocol for a case–control study investigating the clinical phenotypes and genetic regulation of endometriosis in Indian women: the ECGRI study.

  • The relationship between melatonin 1-2 receptor expression in patients with epithelial ovarian cancer and survival.

  • Endometriosis in India: Analysing diagnostic delays, geographic variations, clinical phenotypes and associated characteristics from the ECGRI Study.

  • Predictive value of IL-6, IL-1β, TNF-α, and vaginal pH in diagnosing vaginal microbial infections: A host-inflammatory axis perspective.

  • Identification and characterization of pathogenic microbial flora associated with abnormal vaginal discharge: A microbiological examination study.

  • A pilot study of circulating microRNA-125b as a diagnostic & prognostic biomarker for epithelial ovarian cancer.

  • 2022-RA-195-ESGO miRNA-125b expression in epithelial ovarian cancer.

Conclusion

Kiran Kharsodiya is a dynamic researcher with strong expertise in microbiology, immunology, and clinical research, making significant contributions to women’s health and translational medicine. His blend of academic rigor, practical experience in large-scale trials, and impactful publications positions him as a promising leader in biomedical sciences. With a clear focus on innovation, collaboration, and clinical relevance, he continues to advance knowledge at the crossroads of microbiology and immunology, striving to improve diagnostic and therapeutic outcomes for global healthcare.